Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Position Lessened by Estuary Capital Management LP

Estuary Capital Management LP cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 232,517 shares of the specialty pharmaceutical company's stock after selling 29,040 shares during the quarter. Jazz Pharmaceuticals accounts for about 8.4% of Estuary Capital Management LP's investment portfolio, making the stock its 7th largest holding. Estuary Capital Management LP owned 0.38% of Jazz Pharmaceuticals worth $28,634,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $464,000. Hennion & Walsh Asset Management Inc. increased its position in Jazz Pharmaceuticals by 13.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock worth $4,420,000 after buying an additional 4,332 shares during the period. BTC Capital Management Inc. increased its position in Jazz Pharmaceuticals by 9.4% in the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after buying an additional 4,271 shares during the period. Summit Trail Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $539,000. Finally, Atria Investments Inc increased its position in shares of Jazz Pharmaceuticals by 19.5% during the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock valued at $336,000 after purchasing an additional 445 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer now directly owns 439,307 shares of the company's stock, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares of the company's stock, valued at $4,826,778.66. This represents a 10.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,236 shares of company stock valued at $3,956,190. Corporate insiders own 4.20% of the company's stock.

Analyst Ratings Changes

JAZZ has been the topic of a number of analyst reports. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research report on Wednesday. Royal Bank of Canada lowered their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday. Truist Financial upped their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, StockNews.com cut Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $0.60 during trading hours on Friday, reaching $97.81. The company's stock had a trading volume of 1,217,193 shares, compared to its average volume of 833,461. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a market capitalization of $6.03 billion, a price-to-earnings ratio of 13.78, a PEG ratio of 1.04 and a beta of 0.38. The firm's 50 day simple moving average is $118.96 and its 200-day simple moving average is $122.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company's revenue was down .5% compared to the same quarter last year. During the same period last year, the business earned $2.68 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.